Dr. Hamlin on Future Combination Strategies in the MCL Landscape

Paul A. Hamlin, MD

Paul A. Hamlin, MD, medical oncologist, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses future potential combination strategies in the mantle cell lymphoma (MCL) landscape.

This is likely where researchers are heading as a field, Hamlin explains. In MCL, the focus has really been in incorporating novel agents into treatment paradigms, as well as challenging whether or not autologous stem cell transplantation needs to be part of an induction regimen or whether or not the novel agents can give patients the same benefit in terms of disease control. Nevertheless, US and European investigators are looking at novel combinations, including a BCL-2 inhibitor plus a BCR inhibitor or PI3K inhibitor.

These are active areas of research, especially with incorporating these agents into a backbone of chemotherapy induction.
Printer Printing...